Utility of genetic screening for the prediction of severe arrhythmic outcomes in mitral valve prolapse

The study examined the utility of genetic testing (whole exome sequencing) in identifying patients with mitral valve prolapse who have increased risk of severe arrhythmias. Researchers analyzed 203 patients with mitral valve prolapse and screened for rare genetic variants in 157 arrhythmia-related genes. They found that genetic variants were 4.3 times more common in mitral valve prolapse patients compared to the general population. Pathogenic or likely pathogenic variants were identified in 18 patients (9 percent). Patients carrying these variants had 2.87 times higher risk of severe arrhythmic complications including sudden cardiac arrest. The results suggest that genetic testing may be a useful tool for identifying high-risk patients with mitral valve prolapse.